Trial Site News
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Register
  • Log In
  • News
  • Video
  • Podcast
  • More
Trial Site News
  • News For You
  • Op-Eds
  • Video
  • Podcasts
  • Investor Watch
  • Write for us
  • News for You
  • Op-Eds
  • Video
  • Podcasts
  • Covid-19
  • Investor Watch

Topic: Autoimmune Disease

Lilly Enters into Exclusive Licensing Agreement with Rigel Pharmaceuticals Accessing Promising RIPK1 Inhibitor

Eli Lilly and Co inked a deal to gain worldwide, exclusive licensing rights to the autoimmune and inflammatory disease treatment […]

Lilly Enters into Exclusive Licensing Agreement with Rigel Pharmaceuticals Accessing Promising RIPK1 Inhibitor
2 weeks ago
Share

NeuroGenesis and Hadassah Medical Center Report Significant Results in Patients with Progressive Multiple Sclerosis Treated with NG-01 Autologous Cells Therapy

NeuroGenesis and Hadassah Medical Center announced highly positive results from a placebo-controlled Phase 2 clinical trial assessing the impact of […]

NeuroGenesis and Hadassah Medical Center Report Significant Results in Patients with Progressive Multiple Sclerosis Treated with NG-01 Autologous Cells Therapy
3 months ago
Share

TG Therapeutics Reports Ublituximab Outperforms Sanofi Genzyme’s Aubagio in Relapsing Forms of MS in Two Phase 3 Trials

TG Therapeutics announced positive topline results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab […]

TG Therapeutics Reports Ublituximab Outperforms Sanofi Genzyme’s Aubagio in Relapsing Forms of MS in Two Phase 3 Trials
3 months ago
Share

Exagen Inc. Announces Study to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection

SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients […]

Exagen Inc. Announces Study to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection
4 months ago
Share

OMRF Receives $3.7 million for Autoimmune Disease Research

The National Institutes of Health has awarded the Oklahoma Medical Research Foundation $3.7 million to continue research on Sjögren’s syndrome, […]

OMRF receives $3.7 million for autoimmune disease research
5 months ago
Share

Indiana University & Eli Lilly Ink $5m Research Pact for Patient-Centric, Autoimmune Disease Targets

Indiana University (IU) School of Medicine and Eli Lilly have come together to transform how university research and pharmaceutical companies […]

Indiana University & Eli Lilly Ink $5m Research Pact for Patient-Centric, Autoimmune Disease Targets
5 months ago
Share

Hansa Biopharma Reports Phase 2 Data of Imlifidase in Patients with Severe anti-GBM Antibody Disease

Hansa Biopharma reported data from an investigator-initiated phase 2 trial that evaluated safety, tolerability and efficacy of imlifidase in 15 […]

Hansa Biopharma Reports Phase 2 Data of Imlifidase in Patients with Severe anti-GBM Antibody Disease
5 months ago
Share

KU Leuven Spin-Off Possibly Has New Way to Attack Autoimmune Disease

Why would a new immunotherapy approach be cause for researchers to reconsider Type 1 diabetes and its treatment?  Perhaps a […]

KU Leuven Spin-Off Possibly Has New Way to Attack Autoimmune Disease
6 months ago
Share

Corbus’ Lenabasum Fails to Meet Endpoints in Phase 3 Systemic Sclerosis Trial

Corbus Pharmaceuticals announced topline results from the 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic […]

Corbus' Lenabasum Fails to Meet Endpoints in Phase 3 Systemic Sclerosis Trial
6 months ago
Share

Connect Biopharma Connects to $115m Series C to Progress Autoimmune Disease Drug Candidates

Sino-American biotech Connect Biopharma has collected $115 million in Series C financing led by a new investor, RA Capital Management […]

Connect Biopharma Connects to $115m Series C to Progress Autoimmune Disease Drug Candidates
6 months ago
Share

Posts navigation

Older posts

Latest Podcasts

Alan Cannell talks COVID-19: Nobody Likes Cheap Solutions | Podcast S2 E41

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43

An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Jean-Jacques Rajter and Dr. Juliana Cepelowicz Rajter Discuss Ivermectin In Broward County | Podcast S2 E 27

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.